[go: up one dir, main page]

CL2017003427A1 - Anticuerpos para cd40 - Google Patents

Anticuerpos para cd40

Info

Publication number
CL2017003427A1
CL2017003427A1 CL2017003427A CL2017003427A CL2017003427A1 CL 2017003427 A1 CL2017003427 A1 CL 2017003427A1 CL 2017003427 A CL2017003427 A CL 2017003427A CL 2017003427 A CL2017003427 A CL 2017003427A CL 2017003427 A1 CL2017003427 A1 CL 2017003427A1
Authority
CL
Chile
Prior art keywords
antibodies
rllb
tnvention
administrating
union
Prior art date
Application number
CL2017003427A
Other languages
English (en)
Inventor
Aaron P Yamniuk
Bryan C Barnhart
Brigitte Devaux
Brenda L Stevens
Shannon L Okada
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56322325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017003427(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CL2017003427A1 publication Critical patent/CL2017003427A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE ANTICUERPOS AGONISTAS, O PORCIONES DE UNIÓN AL ANTÍGENO DEL MISMO QUE SE UNEN A CD40 HUMANO. TALES ANTICUERPOS COMPRENDEN OPCIONALMENTE REGIONES FC CON ESPECIFICIDAD MEJORADA PARA FC?RLLB. LA INVENCIÓN TAMBIÉN PROPORCIONA MÉTODOS PARA EL TRATAMIENTO DE CÁNCER O INFECCIÓN CRÓNICA ADMINISTRANDO LOS ANTICUERPOS DE LA TNVENCIÓN A UN SUJETO EN NECESIDAD DEL MISMO.</p>
CL2017003427A 2015-06-29 2017-12-28 Anticuerpos para cd40 CL2017003427A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562186076P 2015-06-29 2015-06-29
US201562252615P 2015-11-09 2015-11-09

Publications (1)

Publication Number Publication Date
CL2017003427A1 true CL2017003427A1 (es) 2018-05-04

Family

ID=56322325

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2017003427A CL2017003427A1 (es) 2015-06-29 2017-12-28 Anticuerpos para cd40
CL2022001189A CL2022001189A1 (es) 2015-06-29 2022-05-04 Anticuerpos para cd40. (divisional de solicitud n° 2017003427)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2022001189A CL2022001189A1 (es) 2015-06-29 2022-05-04 Anticuerpos para cd40. (divisional de solicitud n° 2017003427)

Country Status (18)

Country Link
US (4) US20180142030A1 (es)
EP (1) EP3313880B1 (es)
JP (2) JP7350467B2 (es)
KR (1) KR102671348B1 (es)
CN (2) CN107771184B (es)
AU (2) AU2016285913B2 (es)
BR (1) BR112017027549A2 (es)
CA (1) CA2990012A1 (es)
CL (2) CL2017003427A1 (es)
CO (1) CO2018000809A2 (es)
EA (1) EA035268B1 (es)
ES (1) ES3039629T3 (es)
HK (1) HK1252666A1 (es)
IL (1) IL256499B (es)
MX (2) MX395257B (es)
PE (1) PE20180315A1 (es)
WO (1) WO2017004006A1 (es)
ZA (1) ZA201708704B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE065915T2 (hu) 2011-03-11 2024-06-28 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antitestek és alkalmazásaik
EP3552665A3 (en) 2014-08-12 2019-12-18 Alligator Bioscience AB Antibodies
MX2017016502A (es) * 2015-06-29 2018-03-12 Univ Rockefeller Anticuerpos contra cd40 con actividad agonista mejorada.
EP3307322B1 (en) 2015-09-04 2021-02-17 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof
CA3016534A1 (en) 2016-03-04 2017-09-08 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
DK3468997T5 (da) 2016-06-08 2024-09-09 Xencor Inc Behandling af IgG4-relaterede sygdomme med anti-CD9-antistoffer med tværbinding til CD32B
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
KR102713355B1 (ko) 2017-05-25 2024-10-02 브리스톨-마이어스 스큅 컴퍼니 길항작용 cd40 모노클로날 항체 및 그의 용도
CN110267989B (zh) 2017-06-01 2023-04-04 江苏恒瑞医药股份有限公司 抗cd40抗体、其抗原结合片段及其医药用途
KR102813744B1 (ko) * 2017-12-27 2025-05-28 브리스톨-마이어스 스큅 컴퍼니 항-cd40 항체 및 그의 용도
US12037406B2 (en) * 2018-03-23 2024-07-16 Eli Lilly And Company Anti-CD137 antibodies for combination with anti-PD-L1 antibodies
MX2021000688A (es) * 2018-07-20 2021-03-25 Eucure Beijing Biopharma Co Ltd Anticuerpos anti-cd40 y usos de los mismos.
KR20210040080A (ko) * 2018-07-26 2021-04-12 브리스톨-마이어스 스큅 컴퍼니 암의 치료를 위한 lag-3 조합 요법
AR117091A1 (es) * 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
JP2022509156A (ja) * 2018-11-30 2022-01-20 江蘇恒瑞医薬股▲ふん▼有限公司 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用
CN112839961B (zh) 2018-11-30 2023-04-04 江苏恒瑞医药股份有限公司 一种cd40抗体药物组合物及其用途
US10570210B1 (en) * 2019-03-04 2020-02-25 Beijing Mabworks Biotech Co.Ltd Antibodies binding CD40 and uses thereof
CA3136491A1 (en) 2019-04-10 2020-10-15 Nankai University Anti-cd40 antibodies and uses thereof
WO2021183428A1 (en) 2020-03-09 2021-09-16 Bristol-Myers Squibb Company Antibodies to cd40 with enhanced agonist activity
CN115956086A (zh) * 2020-05-06 2023-04-11 萨摩亚商柏沛生医股份有限公司 用于针对癌症及传染病的免疫疗法的融合蛋白
CN115403670A (zh) * 2021-05-26 2022-11-29 安徽瀚海博兴生物技术有限公司 抗cd40抗体及其用途
EP4384276A4 (en) * 2021-08-10 2025-06-25 Apexigen, Inc. Biomarkers for cd40 agonist therapy
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
CA3167037A1 (en) * 2010-12-20 2012-06-28 The Rockefeller University Modulating agonistic tnfr antibodies
EP3604330A1 (en) 2011-02-25 2020-02-05 Chugai Seiyaku Kabushiki Kaisha Fcgammariib-specific fc antibody
KR20160085888A (ko) 2013-12-20 2016-07-18 에프. 호프만-라 로슈 아게 항-ang2 항체 및 cd40 작용제를 사용한 조합 요법
WO2015145360A1 (en) 2014-03-24 2015-10-01 Glennie Martin J Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof
WO2016028810A1 (en) * 2014-08-18 2016-02-25 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
MX2017016502A (es) * 2015-06-29 2018-03-12 Univ Rockefeller Anticuerpos contra cd40 con actividad agonista mejorada.
CA3016534A1 (en) * 2016-03-04 2017-09-08 The Rockefeller University Antibodies to cd40 with enhanced agonist activity

Also Published As

Publication number Publication date
KR20180021834A (ko) 2018-03-05
EP3313880B1 (en) 2025-08-06
EA201890175A1 (ru) 2018-06-29
MX2022002504A (es) 2022-04-06
KR102671348B1 (ko) 2024-05-30
US20240336695A1 (en) 2024-10-10
AU2022228155A1 (en) 2022-11-10
US10844130B2 (en) 2020-11-24
MX2017016253A (es) 2018-04-20
CN115838427A (zh) 2023-03-24
EP3313880A1 (en) 2018-05-02
JP7350467B2 (ja) 2023-09-26
CA2990012A1 (en) 2017-01-05
IL256499A (en) 2018-02-28
CN107771184B (zh) 2022-11-01
HK1252666A1 (zh) 2019-05-31
WO2017004006A1 (en) 2017-01-05
JP2018526978A (ja) 2018-09-20
MX395257B (es) 2025-03-25
CO2018000809A2 (es) 2018-04-19
EA035268B1 (ru) 2020-05-22
US20210054091A1 (en) 2021-02-25
BR112017027549A2 (pt) 2018-09-11
ZA201708704B (en) 2019-08-28
US20180142030A1 (en) 2018-05-24
PE20180315A1 (es) 2018-02-09
CL2022001189A1 (es) 2023-01-20
AU2016285913A1 (en) 2018-02-15
JP2022028666A (ja) 2022-02-16
ES3039629T3 (en) 2025-10-23
AU2016285913B2 (en) 2022-06-16
IL256499B (en) 2021-12-01
US20190248911A1 (en) 2019-08-15
CN107771184A (zh) 2018-03-06

Similar Documents

Publication Publication Date Title
CL2017003427A1 (es) Anticuerpos para cd40
CY1124033T1 (el) Δοσολογια και χορηγηση μη φουκοζυλιωμενων αντισωματων anti-cd40
UY36757A (es) Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada
BR112018014016A2 (pt) combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer
ECSP17011657A (es) Conjugados de fármacos con anticuerpos anti-cdh6
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201691974A1 (ru) Антитела против ox40 и способы их применения
MX395147B (es) Formulación de anticuerpo anti-cgrp.
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
EA201791884A1 (ru) Химерные антигенные рецепторы против dll3 и способы применения
EA201691991A1 (ru) Мультиспецифические антитела
EA201791310A1 (ru) Химерные антигенные рецепторы к bcma
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201691541A1 (ru) Новые анти-baff антитела
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
CL2017003147A1 (es) Moduladores de receptor nuclear
EA201790529A1 (ru) Новые антитела против mfi2 и способы их применения
CL2017002983A1 (es) Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2
BR112017012381A2 (pt) imunoterapia para doença angiogênica
CU24407B1 (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo
CL2016001753A1 (es) Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
MX2017001686A (es) Anticuerpos anti-ceramida.
EA201790990A1 (ru) Мультипептидный т-специфичный иммунотерапевтический препарат для лечения метастазов рака в головном мозге